3rd Quarter - Report

W STRATEGIES, LLC for GLAXOSMITHKLINE

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R.2430/S.934: FDA Reauthorization Act of 2017. FDA OTC Monograph reform. H.R.1628: American Health Care Act and Better Care Reconciliation Act, including "Cassidy/Graham" bill.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 934 (115th), H.R. 2430 (115th), H.R. 1628 (115th)

Medicare/Medicaid MMM

Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.